文献速递慢性肾脏病

慢性肾脏病患者低密度脂蛋白胆固醇达标情况

Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD.
PubMed 文献 · Kidney Int Rep · 2019-07-30

CKD-REIN 前瞻性队列纳入 3033 例中度(G3)或晚期(G4/G5)CKD 患者。2542 例有基线 LDL-C 测量者中 63% 接受降脂治疗;高危患者中 45% 用他汀和/或依折麦布者达标(<2.6 mmol/l),极高危患者中 G3 期 38%、G4/5 期 29% 达标(<1.8 mmol/l)。降脂治疗强度越高,达标趋势越明显。

要点

  • CKD G3-G5 中符合降脂治疗指征者接受治疗比例不足。
  • 接受降脂治疗者 LDL-C 达标率低,极高危 G4/5 期仅 29% 达标。
  • 降脂治疗强度增加与 LDL-C 达标率升高呈趋势相关。

核心结论

  • 许多符合降脂治疗指征的 CKD G3-G5 患者未接受治疗,接受治疗者很少达到 LDL-C 目标。

研究设计与样本

  • CKD-REIN(NCT03381950)为法国 40 家肾脏科门诊开展的前瞻性队列研究,2013-2016 年纳入 3033 例中度(G3)或晚期(G4/G5)CKD 患者,未接受慢性透析或肾移植,随访 1 年。
  • 分析人群为 2542 例有基线 LDL-C 测量的患者,平均(SD)年龄 67(13)岁,女性占 34%。

主要发现

  • 基线平均(SD)LDL-C 为 2.7(1.1)mmol/l,胆固醇为 4.8(1.3)mmol/l;63% 接受降脂治疗。
  • 24% 为高危(CKD G3 期且无心血管疾病或糖尿病),74% 为极高危(CKD G3 期伴糖尿病或心血管疾病,或 CKD G4/5 期)。
  • 高危患者中,接受他汀和/或依折麦布者 45% 达到 LDL-C 治疗目标(<2.6 mmol/l)。
  • 极高危患者中,CKD G3 期达标(<1.8 mmol/l)比例为 38%,G4/5 期为 29%。
  • 降脂治疗强度越高,LDL-C 达标趋势越明显(中度 vs 低强度调整 OR 1.20,95%CI 0.92-1.56;高强度 vs 低强度调整 OR 1.46,95%CI 1.02-2.09;Ptrend=0.036)。

关键数值与推荐

  • 高危患者 LDL-C 治疗目标为 <2.6 mmol/l;极高危患者目标为 <1.8 mmol/l。

临床怎么用

  • 对 CKD G3-G5 患者应评估降脂治疗指征,未治疗者需考虑启动。
  • 已接受降脂治疗者应监测 LDL-C 是否达到对应风险等级的目标。
  • 极高危 CKD G4/5 期患者达标率尤其低,可考虑加强降脂治疗强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. METHODS: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013-2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients' interviews and medical records. Patients were followed up at 1 year. RESULTS: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92-1.56; high vs. low intensity 1.46; 1.02-2.09; Ptrend = 0.036). CONCLUSION: Many patients with CKD stage G3-G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Massy ZA, Ferrières J, Bruckert E, et al. Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD. Kidney Int Rep. 2019. PMID: 31890996. doi:10.1016/j.ekir.2019.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。